Effects of brucine on vascular endothelial growth factor expression and microvessel density in a nude mouse model of bone metastasis due to breast cancer / 中国结合医学杂志
Chinese journal of integrative medicine
;
(12): 605-609, 2012.
Artigo
em Inglês
| WPRIM
| ID: wpr-347148
ABSTRACT
<p><b>OBJECTIVE</b>To study the effects of brucine on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) in a nude mouse model of bone metastasis due to breast cancer, and to assess the possible antitumor mechanism of brucine.</p><p><b>METHODS</b>A syringe needle was used to directly inject 0.2 mL monoplast suspension (with 2×10(5) human breast cancer cells contained) into the bony femoral cortex of the right hind leg for modeling. Twenty-five nude mice were randomized into five groups and administered with an intraperitoneal injection of saline or drug for 8 consecutive days model group (0.2 mL normal saline), low-dose brucine group (1.73 mg·kg(-1)), medium-dose brucine group (3.45 mg·kg(-1)), high-dose brucine group (6.90 mg·kg(-1)), and thalidomide group (200 mg·kg(-1)). Diet and activity were recorded, and the tumors were harvested 5 weeks later. The percentage of VEGF-positive cells was determined with hematoxylin and eosin staining and immunohistochemical staining, and MVD expression was determined by optical microscopy.</p><p><b>RESULTS</b>The VEGF expressions in brucine- or thalidomide-treated mice were significantly reduced as compared with mice in the model group (P <0.01). There were no significant difference between the high-dose brucine group and the thalidomide group (P >0.05). Significant difference was between the high- and low-dose brucine group P<0.05). Further, VEGF expression was significantly increased in the low- and medium-dose brucine groups compared with the thalidomide group (P <0.05). The MVD values in the three brucine and thalidomide groups were significantly lower than that in the model group (P <0.01). The MVD values in the medium- and high-dose brucine groups were not significantly different from those in the thalidomide group (P >0.05), while the MVD value showed a significant increase in the low-dose group compared with the thalidomide group (P <0.05).</p><p><b>CONCLUSION</b>Brucine could inhibit the growth of breast cancer to bone metastases, possibly by inhibiting tumor angiogenesis.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Patologia
/
Farmacologia
/
Estricnina
/
Neoplasias Ósseas
/
Neoplasias da Mama
/
Imuno-Histoquímica
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Linhagem Celular Tumoral
/
Fator A de Crescimento do Endotélio Vascular
/
Usos Terapêuticos
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo prognóstico
Limite:
Animais
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Chinese journal of integrative medicine
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS